Studies with a 2,4-diamino-5-chloro-quinazoline antifolate: in vitro and invivo correlates in normal and lymphosarcoma dogs.
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism*; D001854:Bone Marrow Cells; D004247:DNA / Q000096:biosynthesis; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003857:Deoxyuridine; D004285:Dogs; D005493:Folic Acid Antagonists / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000494:pharmacology*; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D007939:Leukemia L1210 / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000201:enzymology / Q000378:metabolism*; D008727:Methotrexate / Q000494:pharmacology; D011799:Quinazolines / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000494:pharmacology*; D013942:Thymine Nucleotides; D013997:Time Factors; D014316:Tritium
D004273:DNA, Neoplasm; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013942:Thymine Nucleotides; D014316:Tritium; D004247:DNA; D003857:Deoxyuridine; D008727:Methotrexate